期刊文献+

食管鳞癌组织中HIF-1α和EGFR蛋白的表达与预后的关系 被引量:1

Relationship between the expression of hypoxia-inducible factor-1α,epidermal growth factor receptor and prognosis in patients with esophageal squamous cell carcinoma
暂未订购
导出
摘要 目的研究食管鳞状细胞癌(ESCC)中HIF-1α、EGFR蛋白的表达与食管癌病理特征及预后的关系。方法采用免疫组织化学(SP)法检测116例ESCC组织中HIF-1α、EGFR蛋白的表达,并分析其与临床病理因素及患者生存的关系。结果 HIF-1α与EGFR在ESCC组织中的阳性率分别为63.8%和68.1%,HIF-1α与EGFR均阳性率为50.9%。HIF-1α蛋白的阳性表达与T分期相关(P=0.014)。联合检测HIF-1α和EGFR蛋白均阳性表达与浸润深度及临床分期相关(P=0.006,0.023)。HIF-1α与EGFR蛋白表达呈正相关(r=0.331,P=0.000)。Kaplan-Meier生存分析结果显示,EGFR蛋白阳性表达的ESCC患者生存时间短(P=0.019)。结论 HIF-1α、EGFR蛋白在ESCC组织中呈高表达,二者密切相关,在ESCC发生发展中有重要作用,EGFR可作为判断预后的重要指标。 Objective To investigate the relationship between the expression of epithelial growth factor receptor(EGFR),hy-poxia -inducible factor -1 α(HIF -1 α)and clinical characteristics and prognosis in esophageal squamous cell carcinoma(ES-CC).Methods 1 1 6 cases of ESCC were analyzed about their clinical pathology and survival data.The expression of HIF -1 α, EGFR were detected by immnohistochemical staining.Results The positive rates of high expression of HIF -1 αand EGFR were 63.8% and 68.1 %.Positive rate of co -expression of HIF -1 αand EGFR was 50.9%.The expression of HIF -1 αwas correlated with T stage(P =0.01 4),and the co -expression was correlated with T and TNM stage (P =0.006,0.023). Spearman rank correlation analysis illustrated that there was a significant correlation between HIF -1 αand EGFR.Kaplan -Meier survival analysis showed that high -expression of EGFR were associated with poor survival.Conclusion HIF -1 αand EGFR played an important role in the development and progression of ESCC,and show intimate relationship with biological be-havior.EGFR may be used as an important index to evaluate the prognosis of esophageal carcinoma.
出处 《河南医学研究》 CAS 2015年第5期1-4,共4页 Henan Medical Research
基金 河南省医学科技攻关计划项目(201003125)
关键词 食管肿瘤 鳞状细胞癌 乏氧诱导因子 -1 α 表皮生长因子受体 预后 esophageal neoplasm squamous cell carcinoma hypoxia -inducible factor -1 α epithelial growth factor receptor prognosis
  • 相关文献

参考文献8

  • 1Zhu H, Feng Y, Zhang J, et al. Inhibition of hypoxia inducible factor 1 ct expression suppresses the progression of esophageal squamous cell carcinoma[J]. Cancer Biol Ther,2011,11 ( 11 ) :981 -987.
  • 2Kazi J U, Kabir N N, Flores - Morales A, et al. SOCS proteins in regu- lation of receptor tyrosine kinase signaling [ J ]. Cell Mol Life Sci, 2014,71 (17) :3297 - 3310.
  • 3Can'era S, Senra J, Acosta M I, et al. The role of the HIF - 1 ot tran- scription factor in increased cell division at physiological oxygen ten- sions [ J ]. PLoS One ,2014,9 (5) :979 - 988.
  • 4赵富周,杨鲲鹏,庞志刚,张典,谷博.食管鳞状细胞癌组织中HIF-1α、CCR7和VEGF-C蛋白的表达[J].郑州大学学报(医学版),2011,46(5):660-663. 被引量:5
  • 5Zhu H, Feng Y, Zhang J, et al. Inhibition of hypoxia inducible factor 1 ct expression suppresses the progression of esophageal squamous cell carcinoma [ J ]. Cancer Biol Ther,2011,11 ( 11 ) :981 - 987.
  • 6刘云鹏,徐玲.影响表皮生长因子受体靶向治疗的相关分子检测[J].中华肿瘤杂志,2011,33(2):81-83. 被引量:5
  • 7王军,于金明,景绍武,郭银,武亚晶,李娜,焦文鹏,王丽,张彦军.EGFR过表达与食管鳞癌临床病理特征相关性研究Meta分析[J].中华肿瘤防治杂志,2013,20(22):1767-1772. 被引量:5
  • 8Allon I, Kaplan I, Allon D, et al. HIF - 1 c, VEGF, and EGFR : con- tributing factors in the pathogenesis of necrotizing sialometaplasia[ J ]. Oral Diseases ,2014,20(5 ) :440 -445.

二级参考文献46

  • 1龙志强,李简.食管鳞癌患者组织和血清中VEGF-C的表达[J].郑州大学学报(医学版),2006,41(2):362-364. 被引量:3
  • 2董强刚,韩宝惠,黄进肃,杨立民,黄建,赵春英,卢丽琴.176例非小细胞肺癌的EGFR基因突变分析[J].中华肿瘤杂志,2006,28(9):686-690. 被引量:53
  • 3韩宇,徐建明,段海清,宋三泰,刘晓晴,张扬,张京生.EGFR基因突变与吉非替尼治疗晚期非小细胞肺癌的疗效和预后的关系[J].中华肿瘤杂志,2007,29(4):278-283. 被引量:25
  • 4胡雪君,宋娜,刘云鹏,马艳菊,郝艳艳,康健.非小细胞肺癌中EGFR、VEGF和COX-2表达的预后意义[J].现代肿瘤医学,2007,15(6):772-775. 被引量:3
  • 5Zhu CQ,da Cunha Santos G,Ding K,et al.Role of K-RAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.J Clin Oncol,2008,26:4268-4275.
  • 6Kim ES,Hirsh V,Mok T,et al.Gefitinib versus docetaxel in previously treated non-small-cell lung cancer(INTEREST):a randomised phase Ⅲ trial.Lancet,2008,372:1809-1818.
  • 7Xu JM,Han Y,Duan HQ,et al.EGFR mutations and HER-2/3 protein expression and clinical outcome in Chinese advanced nonsmall cell lung cancer patients treated with gefitinib.J Cancer Res Clin Oncol,2009,135:771-782.
  • 8Karapetis CS,Khambata-Ford S,Jonker DJ,et al.K-ras mutations and benefit from cetuximab in advanced colorectal cancer.N Engl J Med,2008,359:1757-1765.
  • 9Di Nicolantonio F,Martini M,Molinari F,et al.Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.J Clin Oncol,2008,26:5705-5712.
  • 10Loupakis F,Pollina L,Stasi I,et al.PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.J Clin Oncol,2009,27:2622-2629.

共引文献12

同被引文献5

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部